Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats
Identifieur interne : 003526 ( Main/Exploration ); précédent : 003525; suivant : 003527Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats
Auteurs : Concepci Marin [Espagne] ; Esther Aguilar [Espagne] ; José A. Obeso [Espagne]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-05.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- 6‐hydroxydopamine, Analysis of Variance, Animal, Animals, Antiparkinson Agents (therapeutic use), COMT inhibition, Catechols (therapeutic use), Complication, Disease Models, Animal, Drug Therapy, Combination, Dyskinesia, Dyskinesias (drug therapy), Dyskinesias (etiology), Entacapone, Levodopa, Levodopa (therapeutic use), Male, Nervous system diseases, Nitriles, Oxidopamine (toxicity), Parkinson disease, Parkinson's disease, Parkinsonian Disorders (chemically induced), Parkinsonian Disorders (complications), Parkinsonian Disorders (drug therapy), Rat, Rats, Rats, Sprague-Dawley, Severity of Illness Index, Time Factors, motor complications.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Catechols, Levodopa.
- chemically induced : Parkinsonian Disorders.
- complications : Parkinsonian Disorders.
- drug therapy : Dyskinesias, Parkinsonian Disorders.
- etiology : Dyskinesias.
- chemical , toxicity : Oxidopamine.
- Analysis of Variance, Animals, Disease Models, Animal, Drug Therapy, Combination, Male, Nitriles, Rats, Rats, Sprague-Dawley, Severity of Illness Index, Time Factors.
Abstract
Levodopa‐induced dyskinesias (LIDs) have been associated with a sequence of events that includes pulsatile stimulation of dopamine receptors. The degree of nigrostriatal degeneration, the half‐life of dopaminomimetic agents, and the dose of levodopa used to treat parkinsonian symptoms are factors directly correlated with the development of motor complications in Parkinson's disease patients. Long‐acting agents producing continuous dopaminergic stimulation are less likely to prime for dyskinesia than short‐acting drugs that produce pulsatile stimulation of dopamine receptors. Inhibition of the enzyme catechol‐O‐methyl transferase (COMT) by entacapone extends the half‐life of levodopa and minimizes variability in plasma levodopa levels. The aim of the present study was to characterize the effect of the early administration of the COMT inhibitor entacapone in the recently described model of LIDs in rats with a nigrostriatal lesion induced by 6‐hydroxydopamine (6‐OHDA). Male Sprague–Dawley rats received a unilateral 6‐OHDA administration in the nigrostriatal pathway. Animals were treated either with levodopa (6 mg/kg, twice at day, i.p.) plus entacapone (30 mg/kg per day, i.p.) or levodopa (6 mg/kg, twice at day, i.p.) plus vehicle for 22 consecutive days. Early administration of entacapone, in association with levodopa, induces a decrease in the severity of dyskinesia and delays their onset in hemiparkinsonian rats. All dyskinesia subtypes evaluated, such as axial, limb, and orofacial dyskinesias, have shown similar reductions. These results suggest that entacapone, by extending levodopa elimination half‐life, might reduce its propensity to induce motor complications. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.20780
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000691
- to stream Istex, to step Curation: 000691
- to stream Istex, to step Checkpoint: 001F86
- to stream PubMed, to step Corpus: 002D80
- to stream PubMed, to step Curation: 002D80
- to stream PubMed, to step Checkpoint: 002E13
- to stream Ncbi, to step Merge: 001549
- to stream Ncbi, to step Curation: 001549
- to stream Ncbi, to step Checkpoint: 001549
- to stream Main, to step Merge: 004840
- to stream PascalFrancis, to step Corpus: 001B54
- to stream PascalFrancis, to step Curation: 001167
- to stream PascalFrancis, to step Checkpoint: 001B76
- to stream Main, to step Merge: 004C71
- to stream Main, to step Curation: 003526
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats</title><author><name sortKey="Marin, Concepci" sort="Marin, Concepci" uniqKey="Marin C" first="Concepci" last="Marin">Concepci Marin</name></author><author><name sortKey="Aguilar, Esther" sort="Aguilar, Esther" uniqKey="Aguilar E" first="Esther" last="Aguilar">Esther Aguilar</name></author><author><name sortKey="Obeso, Jose A" sort="Obeso, Jose A" uniqKey="Obeso J" first="José A." last="Obeso">José A. Obeso</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D50A17C9672F436060EB10B3E7667ED5132763FB</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.20780</idno><idno type="url">https://api.istex.fr/document/D50A17C9672F436060EB10B3E7667ED5132763FB/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000691</idno><idno type="wicri:Area/Istex/Curation">000691</idno><idno type="wicri:Area/Istex/Checkpoint">001F86</idno><idno type="wicri:doubleKey">0885-3185:2006:Marin C:coadministration:of:entacapone</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16437585</idno><idno type="wicri:Area/PubMed/Corpus">002D80</idno><idno type="wicri:Area/PubMed/Curation">002D80</idno><idno type="wicri:Area/PubMed/Checkpoint">002E13</idno><idno type="wicri:Area/Ncbi/Merge">001549</idno><idno type="wicri:Area/Ncbi/Curation">001549</idno><idno type="wicri:Area/Ncbi/Checkpoint">001549</idno><idno type="wicri:doubleKey">0885-3185:2006:Marin C:coadministration:of:entacapone</idno><idno type="wicri:Area/Main/Merge">004840</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:06-0289030</idno><idno type="wicri:Area/PascalFrancis/Corpus">001B54</idno><idno type="wicri:Area/PascalFrancis/Curation">001167</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001B76</idno><idno type="wicri:doubleKey">0885-3185:2006:Marin C:coadministration:of:entacapone</idno><idno type="wicri:Area/Main/Merge">004C71</idno><idno type="wicri:Area/Main/Curation">003526</idno><idno type="wicri:Area/Main/Exploration">003526</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats</title><author><name sortKey="Marin, Concepci" sort="Marin, Concepci" uniqKey="Marin C" first="Concepci" last="Marin">Concepci Marin</name><affiliation wicri:level="3"><country xml:lang="fr">Espagne</country><wicri:regionArea>Laboratori de Neurologia Experimental, Fundació Clínic‐Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Aguilar, Esther" sort="Aguilar, Esther" uniqKey="Aguilar E" first="Esther" last="Aguilar">Esther Aguilar</name><affiliation wicri:level="3"><country xml:lang="fr">Espagne</country><wicri:regionArea>Laboratori de Neurologia Experimental, Fundació Clínic‐Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Barcelona</wicri:regionArea><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Obeso, Jose A" sort="Obeso, Jose A" uniqKey="Obeso J" first="José A." last="Obeso">José A. Obeso</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Neurology and Neurosurgery, Neuroscience Area, Clinica Universitaria and Medical School, University of Navarra and FIMA, Pamplona</wicri:regionArea><wicri:noRegion>Pamplona</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-05">2006-05</date><biblScope unit="vol">21</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="646">646</biblScope><biblScope unit="page" to="653">653</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">D50A17C9672F436060EB10B3E7667ED5132763FB</idno><idno type="DOI">10.1002/mds.20780</idno><idno type="ArticleID">MDS20780</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>6‐hydroxydopamine</term><term>Analysis of Variance</term><term>Animal</term><term>Animals</term><term>Antiparkinson Agents (therapeutic use)</term><term>COMT inhibition</term><term>Catechols (therapeutic use)</term><term>Complication</term><term>Disease Models, Animal</term><term>Drug Therapy, Combination</term><term>Dyskinesia</term><term>Dyskinesias (drug therapy)</term><term>Dyskinesias (etiology)</term><term>Entacapone</term><term>Levodopa</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Nervous system diseases</term><term>Nitriles</term><term>Oxidopamine (toxicity)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Parkinsonian Disorders (chemically induced)</term><term>Parkinsonian Disorders (complications)</term><term>Parkinsonian Disorders (drug therapy)</term><term>Rat</term><term>Rats</term><term>Rats, Sprague-Dawley</term><term>Severity of Illness Index</term><term>Time Factors</term><term>motor complications</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Catechols</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesias</term><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesias</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>Oxidopamine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term><term>Animals</term><term>Disease Models, Animal</term><term>Drug Therapy, Combination</term><term>Male</term><term>Nitriles</term><term>Rats</term><term>Rats, Sprague-Dawley</term><term>Severity of Illness Index</term><term>Time Factors</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Animal</term><term>Complication</term><term>Dyskinésie</term><term>Entacapone</term><term>Lévodopa</term><term>Parkinson maladie</term><term>Rat</term><term>Système nerveux pathologie</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Levodopa‐induced dyskinesias (LIDs) have been associated with a sequence of events that includes pulsatile stimulation of dopamine receptors. The degree of nigrostriatal degeneration, the half‐life of dopaminomimetic agents, and the dose of levodopa used to treat parkinsonian symptoms are factors directly correlated with the development of motor complications in Parkinson's disease patients. Long‐acting agents producing continuous dopaminergic stimulation are less likely to prime for dyskinesia than short‐acting drugs that produce pulsatile stimulation of dopamine receptors. Inhibition of the enzyme catechol‐O‐methyl transferase (COMT) by entacapone extends the half‐life of levodopa and minimizes variability in plasma levodopa levels. The aim of the present study was to characterize the effect of the early administration of the COMT inhibitor entacapone in the recently described model of LIDs in rats with a nigrostriatal lesion induced by 6‐hydroxydopamine (6‐OHDA). Male Sprague–Dawley rats received a unilateral 6‐OHDA administration in the nigrostriatal pathway. Animals were treated either with levodopa (6 mg/kg, twice at day, i.p.) plus entacapone (30 mg/kg per day, i.p.) or levodopa (6 mg/kg, twice at day, i.p.) plus vehicle for 22 consecutive days. Early administration of entacapone, in association with levodopa, induces a decrease in the severity of dyskinesia and delays their onset in hemiparkinsonian rats. All dyskinesia subtypes evaluated, such as axial, limb, and orofacial dyskinesias, have shown similar reductions. These results suggest that entacapone, by extending levodopa elimination half‐life, might reduce its propensity to induce motor complications. © 2006 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Espagne</li></country><region><li>Catalogne</li></region><settlement><li>Barcelone</li></settlement></list><tree><country name="Espagne"><region name="Catalogne"><name sortKey="Marin, Concepci" sort="Marin, Concepci" uniqKey="Marin C" first="Concepci" last="Marin">Concepci Marin</name></region><name sortKey="Aguilar, Esther" sort="Aguilar, Esther" uniqKey="Aguilar E" first="Esther" last="Aguilar">Esther Aguilar</name><name sortKey="Obeso, Jose A" sort="Obeso, Jose A" uniqKey="Obeso J" first="José A." last="Obeso">José A. Obeso</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003526 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003526 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D50A17C9672F436060EB10B3E7667ED5132763FB
|texte= Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats
}}
| This area was generated with Dilib version V0.6.23. |  |